

Special Issue

Cytochrome P450 (CYP) in Health and Disease

Message from the Guest Editor

Human cytochrome P450 enzymes play a crucial role in various biological processes and human diseases. Many P450s metabolize drugs used to treat human diseases. Aside from this prominent function, other P450s are necessary for the synthesis of endogenous compounds essential for human physiology. On some occasions, alterations of specific P450s affect the biological processes that they mediate and lead to disease. P450 substrates are exogenous chemicals with potential pathogenic properties. Clinically important P450s are enzymes that act on major endogenous substrates and in many cases control their levels. Therefore, a change in the activity of these P450s often causes severe human diseases. In addition, to date, it remains a challenge to elucidate the role of P450s in the development of chronic diseases. Genetic polymorphism of P450 enzymes and nongenetic factors affecting the expression and activity of these proteins have substantial biological and pathological consequences. Original manuscripts and reviews dealing with all aspects of the cytochrome P450 superfamily in health and disease are invited to this Special Issue for peer review, to be considered for publication.

Guest Editor

Prof. Dr. Grishanova Alevtina

Institute of Molecular Biology and Biophysics, Federal Research Center of Fundamental and Translational Medicine, Timakova Str. 2/12, 630117 Novosibirsk, Russia

Deadline for manuscript submissions

closed (30 June 2023)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/112651

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).